By 2020, the global market for specific drugs will reach US $1.4 trillion

Source: yiyanwang 2015-12-10 IMS Medical Information Research Institute report said: in the next five years, the global drug cost will be significantly increased The Institute said: by 2020, the global drug expenditure is expected to soar to $1.4 trillion, which will increase by nearly a third compared with 2015, or by $349 billion According to the IMS Institute's annual report on drug expenditure, high price drugs will increase drug expenditure, and patients like hepatitis C and cancer will be able to buy cheaper drugs through more channels, or receive innovative therapies, which will also increase drug expenditure The sales volume of anticancer drugs, hepatitis C drugs and drugs for the treatment of autoimmune diseases is the largest, and the sales volume of specific drugs will continue to increase sharply until 2020 Sales of anti-cancer drugs are expected to reach $100 billion to $120 billion in 2020, which is encouraging news for companies such as Roche and Novartis, which are growing stronger in the field of anti-cancer Companies such as Biogen, Sanofi and Merck KGaA are also worth mentioning: in 2020, these companies have autoimmune drugs, including anti multiple sclerosis drugs, whose sales are expected to reach US $55 billion to US $65 billion, an increase of 15% Hepatitis C drugs will also drive sales growth, a bright spot for companies such as Gilead Sciences, Bristol Myers and abbvie, which Merck & Co will soon explore In 2020, the sales volume of antiviral hepatitis C drugs is expected to increase by 10%, reaching US $44 billion to US $55 billion, becoming a large category of drugs in the field of medicine Just a few years ago, the sales of such drugs accounted for only a small part of the medical field According to a statement by the IMS Research Institute, the Institute estimates that by 2020 about 36 million people will be taking certain life-saving hepatitis C drugs, "a remarkable achievement for hepatitis C, which has been difficult to treat for decades." As more patients in developing countries have access to new drugs, growth in emerging markets will play a role in this process According to the prediction of IMS Research Institute, the sales of specific drugs in developing countries will increase by 24% by 2020, among which India, China, Brazil and Indonesia will play the most important role in promoting drug expenditure By 2020, China's drug spending will be the highest, between $160 billion and $190 billion, but the growth trend is likely to be weaker in the next five years For companies focused on innovation, substantial growth is likely to come In a conference call related to the annual report, Murray Aitken, executive director of the IMS Research Institute, said: the Institute expects a large number of innovative drugs to emerge, and 225 new drugs will enter the market by 2020 About a third of research and development of innovative drugs will focus on cancer treatment, and pharmaceutical companies will have a chance to make big profits as they invest in promising therapies, Aitken said At the same time, as the sales of cheap drugs around the world will increase, cheap drugs will also promote the increase of drug expenses With the increasing number of drugs with expired patent protection, generic drugs will continue to have a negative impact on the sales of brand drugs Biologicals will only make the sales of branded drugs worse, which is expected to reduce the sales of branded drugs by $41 billion due to the popularity of biologicals in the market The impact of biosimilars on Europe will be particularly severe, as there is already legislation in Europe that supports the use of biosimilars.